Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
$76.29+1.15%
Close 2026-07-07 · 1-day change
Reading ZTS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZTS free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
Reading ZTS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZTS free→QuarterlyIQ Insights · ZTS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 14 valuation methods, at three horizons. Current price $76.29. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $76 ZTS trades at 12× p/e, below its 25× p/e peer median. Our $96 fair value sits well above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $85–$130. Not investment advice.
$85.00 – $130.00 (median $97.00) · 8 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $5.65/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $97.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $144.78 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $158.25 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $27.44 | — | — | TTM | high |
| graham number | 12M | $33.38 | — | — | TTM | high |
| Mgmt guidance | 12M | $174.26 | 25.2 | 6.92 | Mgmt | high |
| Peer EV/EBITDA | 12M | $67.10 | 9.3 | 9.01 | TTM | high |
| Peer P/FCF | 12M | $85.44 | 16.9 | 5.06 | TTM | high |
| Peer P/E | 12M | $162.81 | 25.2 | 6.47 | TTM | high |
| Peer P/S | 12M | $57.54 | 2.6 | 22.56 | TTM | high |
| PEG | 12M | $58.92 | 9.1 | 6.47 | TTM | high |
| residual income | 12M | $30.57 | — | — | TTM | high |
| Own P/E history | 12M | $161.70 | 25.0 | 6.47 | TTM | high |
| triangulated | 12M | $157.61 | 25.2 | 6.26 | Triangulated | high |
| Mgmt guidance | 3Y | $228.34 | 25.2 | 9.07 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $125.16 | 16.9 | 7.41 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $195.08 | 25.2 | 7.75 | Analyst | medium |
| Peer P/S | 3Y | $64.39 | 2.6 | 25.25 | guidance | medium |
| PEG | 3Y | $70.60 | 9.1 | 7.75 | Analyst | medium |
| Own P/E history | 3Y | $193.75 | 25.0 | 7.75 | Analyst | medium |
| Mgmt guidance | 5Y | $273.43 | 25.2 | 10.87 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $161.45 | 16.9 | 9.56 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $207.09 | 25.2 | 8.23 | Analyst | high |
| Peer P/S | 5Y | $68.36 | 2.6 | 26.81 | guidance | high |
| PEG | 5Y | $74.94 | 9.1 | 8.23 | Analyst | high |
| Own P/E history | 5Y | $205.68 | 25.0 | 8.23 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.